These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31260625)

  • 1. Assessing the Impact of Endogenously Derived Crystalline Drug on the in Vivo Performance of Amorphous Formulations.
    Purohit HS; Trasi NS; Osterling DJ; Stolarik DF; Jenkins GJ; Gao W; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Aug; 16(8):3617-3625. PubMed ID: 31260625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Crystallization Tendency of Commercially Available Amorphous Tacrolimus Formulations Exposed to Different Stress Conditions.
    Trasi NS; Purohit HS; Taylor LS
    Pharm Res; 2017 Oct; 34(10):2142-2155. PubMed ID: 28687987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory In Vitro Dissolution Testing and Physiologically Based Pharmacokinetic Modeling and Simulation.
    Purohit HS; Trasi NS; Sun DD; Chow ECY; Wen H; Zhang X; Gao Y; Taylor LS
    J Pharm Sci; 2018 May; 107(5):1330-1341. PubMed ID: 29289674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Sink Dissolution Behavior and Solubility Limit of Commercial Tacrolimus Amorphous Formulations.
    Trasi NS; Purohit HS; Wen H; Sun DD; Taylor LS
    J Pharm Sci; 2017 Jan; 106(1):264-272. PubMed ID: 27816263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method.
    Wang Y; Han X; Wang J; Wang Y
    Int J Pharm; 2016 May; 505(1-2):35-41. PubMed ID: 27034003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorptive Dissolution Testing: An Improved Approach to Study the Impact of Residual Crystallinity on the Performance of Amorphous Formulations.
    Hate SS; Reutzel-Edens SM; Taylor LS
    J Pharm Sci; 2020 Mar; 109(3):1312-1323. PubMed ID: 31765652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion.
    Knopp MM; Wendelboe J; Holm R; Rades T
    Eur J Pharm Biopharm; 2018 Sep; 130():290-295. PubMed ID: 30064702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebulization of nanoparticulate amorphous or crystalline tacrolimus--single-dose pharmacokinetics study in mice.
    Sinswat P; Overhoff KA; McConville JT; Johnston KP; Williams RO
    Eur J Pharm Biopharm; 2008 Aug; 69(3):1057-66. PubMed ID: 18406587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aminoalkyl methacrylate copolymer E/HCl on in vivo absorption of poorly water-soluble drug.
    Yoshida T; Kurimoto I; Yoshihara K; Umejima H; Ito N; Watanabe S; Sako K; Kikuchi A
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1698-705. PubMed ID: 23062024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing an ADME liquid formulation with matching exposures to an amorphous dosage form.
    Xi H; Yang Z; Tatavarti A; Xu W; Fuerst J; Ormes J
    Int J Pharm; 2019 Jan; 554():48-53. PubMed ID: 30236644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles.
    Kwon M; Yeom D; Kim NA; Choi du H; Park J; Wang H; Yoo SD; Jeong SH
    Arch Pharm Res; 2015 Jan; 38(1):73-80. PubMed ID: 24627339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
    Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
    Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics.
    Rahman Z; Siddiqui A; Bykadi S; Khan MA
    Int J Pharm; 2014 Nov; 475(1-2):462-70. PubMed ID: 25173870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
    Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
    Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
    Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.
    Onoue S; Kojo Y; Aoki Y; Kawabata Y; Yamauchi Y; Yamada S
    Drug Metab Pharmacokinet; 2012; 27(4):379-87. PubMed ID: 22240843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.